Opportunity Information: Apply for PAR 22 100
The National Institutes of Health (NIH) funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-22-100) supports short, focused clinical research projects that help rare disease programs get ready for future clinical trials, without actually running a clinical trial under this award. The core idea is to tackle practical, high-impact gaps that often slow rare disease development programs down right before the trial stage. NIH is looking for projects that make it easier to move promising therapeutics or diagnostics toward trials efficiently and responsibly, and that improve the odds that those eventual trials will produce clear, interpretable results.
The emphasis is on "clinical trial readiness," meaning work that strengthens the foundations needed to design and execute a good trial later. In practice, this commonly includes developing, refining, and testing biomarkers that can be measured reliably and that track disease biology or treatment response. It also includes developing and evaluating clinical outcome assessment measures, such as clinician-reported outcomes, patient-reported outcomes, performance outcomes, or other endpoints that can serve as meaningful and defensible measures of benefit. Another major area is natural history and disease characterization work: carefully defining how a rare disease presents, how it progresses over time, what the major sources of variability are across patients, and what time windows and milestones matter most. That kind of information is often essential for choosing endpoints, determining trial duration, estimating sample sizes, and selecting the right patient population and inclusion criteria.
Because this is an R03 mechanism, applicants should generally think in terms of discrete, well-scoped projects rather than large multi-year programs. While the announcement does not list an award ceiling or expected number of awards in the provided text, the R03 format typically aligns with smaller budgets and shorter timelines compared to larger NIH grants, and it is usually best suited for tightly defined deliverables (for example, validating a candidate biomarker assay in a small cohort, piloting the feasibility and measurement properties of an outcome measure, or generating key natural history data elements needed to design a later trial).
A key restriction is embedded in the title: "Clinical Trial Not Allowed." That means the funded work should not be an interventional clinical trial that prospectively assigns human participants to receive an experimental treatment to evaluate health outcomes. Instead, the program supports preparatory clinical studies that may involve human participants and clinical data collection, but are aimed at readiness activities such as endpoint development, biomarker qualification groundwork, observational studies, or other clinical research that de-risks and informs subsequent trial planning. The practical takeaway is that applicants should frame their aims around tools, measures, and disease understanding that enable trials, rather than testing an intervention for efficacy.
Eligibility is broad and includes many types of U.S.-based organizations and government entities. Eligible applicants listed in the source include state, county, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized. Nonprofit organizations are eligible whether or not they hold 501(c)(3) status (as long as they are not institutions of higher education), and for-profit organizations are also eligible (excluding small businesses in that category, since small businesses are separately included as eligible). Small businesses are explicitly eligible as well. The FOA also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
On foreign participation, the rules are specific. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) institutions are not eligible to apply directly, and non-domestic components of U.S. organizations are not eligible to apply. However, "foreign components" are allowed as defined by the NIH Grants Policy Statement. In other words, a U.S. applicant organization can include certain international elements in the project (for example, a defined collaboration, data collection site, or specialized analysis) if it meets NIH's definition and requirements for a foreign component, but a foreign institution cannot be the applicant organization.
From an administrative standpoint, this is a discretionary grant in the health area, administered by NIH, and is associated with CFDA numbers 93.350 and 93.865. The original closing date shown in the source data is 2023-04-13, and the FOA creation date is 2022-02-03. Applicants considering similar opportunities should verify current deadlines and any updated NIH notices, since submission dates and policies can change through reissues or updates even when the scientific goals remain similar.
Overall, the FOA is best understood as support for the clinical groundwork that makes rare disease trials possible and more likely to succeed: stronger biomarkers, better endpoints, clearer natural history, and better-informed trial designs for candidate therapeutics or diagnostics that are nearing the point where a trial would be the next step.Apply for PAR 22 100
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.350, 93.865.
- This funding opportunity was created on 2022-02-03.
- Applicants must submit their applications by 2023-04-13. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the NIH opportunity PAR-22-100?
PAR-22-100 is an NIH funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)." It supports short, focused clinical research projects that help rare disease programs prepare for future clinical trials, without conducting a clinical trial under this award.
What is the main goal of this funding opportunity?
The main goal is to address practical, high-impact gaps that commonly slow rare disease development programs right before they are ready to start a clinical trial. The intent is to strengthen the scientific and operational foundations needed to design and execute strong future trials that yield clear, interpretable results.
What does "clinical trial readiness" mean in this FOA?
In this FOA, "clinical trial readiness" refers to research that improves the ability to design and run a high-quality clinical trial later. This includes building the evidence and tools needed for trial design decisions, such as endpoints, biomarkers, and an understanding of disease progression and variability.
Are clinical trials allowed under this R03?
No. The FOA title includes "Clinical Trial Not Allowed," meaning the funded work must not be an interventional clinical trial that prospectively assigns human participants to receive an experimental treatment to evaluate health outcomes.
If clinical trials are not allowed, what types of studies can be supported?
The FOA supports preparatory clinical research that may involve human participants and clinical data collection, as long as the purpose is readiness activities rather than testing an intervention for efficacy. Examples described include observational studies, endpoint development, biomarker-related work, and natural history or disease characterization studies that de-risk and inform future trial planning.
What kinds of scientific activities are emphasized?
The FOA emphasizes work that strengthens foundations needed for later trials, commonly including biomarker development and evaluation, clinical outcome assessment measure development and evaluation, and natural history and disease characterization activities.
What is meant by biomarker work in this context?
Biomarker-related readiness work commonly includes developing, refining, and testing biomarkers that can be measured reliably and that reflect disease biology or treatment response. The focus is on producing tools and evidence that can support endpoint selection and interpretability in later trials.
What are "clinical outcome assessment" measures, and why are they included?
Clinical outcome assessment (COA) measures are tools used to measure clinical benefit or meaningful change. The FOA references clinician-reported outcomes, patient-reported outcomes, performance outcomes, and other endpoints that can serve as defensible measures of benefit in future trials.
What types of natural history work fit the FOA?
Natural history and disease characterization work includes carefully defining how a rare disease presents, how it progresses over time, what variability exists across patients, and which time windows and milestones matter. This information can support later trial decisions such as endpoint choice, trial duration, sample size estimation, and inclusion criteria.
Why does NIH emphasize natural history and variability for rare diseases?
Because rare diseases often have limited prior data, understanding progression and sources of variability is frequently essential for designing trials that can produce clear, interpretable results. The FOA highlights that these data inform endpoints, duration, sample sizes, and selecting the right patient population.
What does the R03 mechanism imply about project scope?
The R03 mechanism generally aligns with discrete, well-scoped projects rather than large multi-year programs. The FOA description suggests aiming for tightly defined deliverables appropriate for a smaller, short, focused effort.
Does the FOA specify a budget cap or number of awards?
Not in the information provided here. While the text notes the R03 format typically aligns with smaller budgets and shorter timelines than larger NIH grants, it also states that an award ceiling and expected number of awards are not listed in the provided text.
What are examples of deliverables that match the intended scope?
Examples described include validating a candidate biomarker assay in a small cohort, piloting the feasibility and measurement properties of an outcome measure, or generating key natural history data elements needed to design a later trial.
Can a project involve human participants?
Yes, projects may involve human participants and clinical data collection, as long as the work is preparatory and focused on readiness (for example, observational studies, endpoint development, biomarker groundwork, or natural history studies), and does not constitute a prohibited clinical trial.
What is the practical "do not do" restriction applicants should keep in mind?
Applicants should not propose an interventional clinical trial that assigns participants to an experimental treatment to evaluate health outcomes. The aims should be framed around tools, measures, and disease understanding that enable later trials rather than testing an intervention for efficacy.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and government entities. Eligible applicants listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized.
Are nonprofits eligible?
Yes. Nonprofit organizations are eligible whether or not they have 501(c)(3) status, as long as they are not institutions of higher education (since institutions of higher education are listed separately in the eligibility description).
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, and small businesses are explicitly eligible as well.
Are small businesses eligible?
Yes. Small businesses are explicitly included as eligible applicants.
Are specific types of institutions highlighted as eligible?
Yes. The FOA highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations.
Are federal agencies eligible applicants?
Yes. Eligible federal agencies are listed among additional eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among the eligible applicants listed.
Can a non-U.S. (foreign) institution apply directly as the applicant organization?
No. Non-domestic (non-U.S.) entities and non-domestic institutions are not eligible to apply directly, and non-domestic components of U.S. organizations are not eligible to apply.
Are any international activities allowed at all?
Yes. "Foreign components" are allowed as defined by the NIH Grants Policy Statement. This means a U.S. applicant may include certain international elements (such as a collaboration, data collection site, or specialized analysis) if it meets NIH's definition and requirements for a foreign component.
What is the awarding agency and what type of grant is this?
The awarding agency is the National Institutes of Health (NIH). It is described as a discretionary grant in the health area.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.350 and 93.865.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR-22-100.
What was the FOA creation date listed in the provided information?
The FOA creation date shown is 2022-02-03.
What was the original closing date listed in the provided information?
The original closing date shown is 2023-04-13.
Should applicants rely on the closing date listed here?
The provided information notes that applicants should verify current deadlines and any updated NIH notices, since submission dates and policies can change through reissues or updates even when scientific goals remain similar.
What kinds of programs is this FOA best suited for?
It is best suited for rare disease programs that are approaching the trial stage and need key clinical groundwork to proceed efficiently and responsibly, such as stronger biomarkers, better endpoints, clearer natural history, and better-informed trial design inputs for candidate therapeutics or diagnostics.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: Farmed Cervid Chronic Wasting Disease Management and Response Activities 2022 Cooperative Agreements
Previous opportunity: FY 2022 Cooperative Endangered Species Conservation Fund (CESCF) Traditional Conservation Grants Program (Service Legacy Region 3)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 100
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 100) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed) Apply for RFA AI 22 015 Funding Number: RFA AI 22 015 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $700,000 |
| CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect (P50) (Clinical Trial Optional) Apply for RFA HD 23 007 Funding Number: RFA HD 23 007 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50) (Clinical Trial Optional) Apply for RFA HD 23 011 Funding Number: RFA HD 23 011 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,100,000 |
| NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional) Apply for RFA HD 23 002 Funding Number: RFA HD 23 002 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $220,000 |
| NICHD Neonatal Research Network (NRN): Data Coordinating Center (U24 Clinical Trial Optional) Apply for RFA HD 23 001 Funding Number: RFA HD 23 001 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Maternal-Fetal Medicine Units (MFMU) Network: Clinical Centers (UG1 Clinical Trial Optional) Apply for RFA HD 23 016 Funding Number: RFA HD 23 016 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $2,200,000 |
| NICHD Maternal-Fetal Medicine Units (MFMU) Network: Data Coordinating Center (U24 Clinical Trial Optional) Apply for RFA HD 23 017 Funding Number: RFA HD 23 017 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) Apply for PAR 22 167 Funding Number: PAR 22 167 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional) Apply for RFA HD 23 026 Funding Number: RFA HD 23 026 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| Bioprinted Tissue Constructs for Obstetric, Gynecologic, and Pediatric Applications (R01 Clinical Trial Optional) Apply for RFA HD 23 004 Funding Number: RFA HD 23 004 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $500,000 |
| Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) Apply for RFA AR 23 001 Funding Number: RFA AR 23 001 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| HEAL Initiative: Coordinated Pain Care in Health Care Systems Research Program - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA NS 22 065 Funding Number: RFA NS 22 065 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2023 (R24 Clinical Trial Not Allowed) Apply for RFA HD 23 027 Funding Number: RFA HD 23 027 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $120,000 |
| Contraceptive Development Research Center (P50 Clinical Trial Optional) Apply for RFA HD 23 029 Funding Number: RFA HD 23 029 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,300,000 |
| NICHD Global Network for Womens and Childrens Health Research: Research Units (UG1 Clinical Trial Optional) Apply for RFA HD 23 008 Funding Number: RFA HD 23 008 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $365,000 |
| NICHD Global Network for Womens and Childrens Health Research: Data Coordinating Center (U24 Clinical Trial Optional) Apply for RFA HD 23 009 Funding Number: RFA HD 23 009 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) Apply for PAR 22 222 Funding Number: PAR 22 222 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed) Apply for PAR 22 215 Funding Number: PAR 22 215 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed) Apply for RFA HD 23 012 Funding Number: RFA HD 23 012 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $920,000 |
| Pediatric Scientist Development Program (PDSP) (K12 Clinical Trial Not Allowed) Apply for RFA HD 23 034 Funding Number: RFA HD 23 034 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 100", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.